Ciprofloxacin in Respiratory Tract Infections
DOI:
https://doi.org/10.5915/23-1-14377Keywords:
Quinolone, Ciprofloxacin, Respiratory Tract InfectionAbstract
DOI: http://dx.doi.org/10.5915/23-1-14377
Of the quinolone class of antimicrobials, only oral ciprofloxacin is currently approved for respiratory indications. Ciprofloxacin has good tissue penetration and is active against most gram-negative and gram-positive pathogens, including Staplylococcus sp. It is, however, less effective against anaerobic bacteria and Streptococcus pneumoniae. The drug may be useful for managing bacterial exacerbations of COPD and for treating elderly patients with respiratory tract infections, including nosocomial pneumonias. Ciprofloxacin probably alters metabolism of theophylline and some antacids interfere with its absorption and antibacterial activity.
Downloads
Published
1991-01-01
Issue
Section
Review Articles
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
